



Precision Health for Metabolic Disease and Cancer

January 2025

Global market leader for AI-driven medical imaging

Leading diagnostics partner

4

regulatory cleared products

6

large pharma contracts

3

in late phase development

>75

clinical trials have used
Perspectum imaging

Strong access to datasets, knowledge and growing installed based

>100,000

data sets, paired with
biochemistry and genetics

280

employees and 70+ PhDs

750+

scanners worldwide enabled with
Perspectum technology

Rapidly growing with clear line of sight to profitability

>\$25mm

revenue

>30%


YoY growth CAGR

>80%

gross margins


Data-driven, Quantitative Disease Assessment with AI across Organs

LiverMultiScan



Liver Disease

MRCP+



Biliary and Pancreatic Disease

Hepatica




Liver Cancer

CoverScan



Multi-Organ Disease


Company Milestones




Perspectum Extracts Quantitative, Actionable and Objective Information from Images to Inform Clinical Decision Making



Non-contrast
MRI scan



Digital, quantitative
biomarkers



Actionable reports



Better decision
support and care

Standardized across major
MRI manufacturers

Commercialized via
Software-as-a-Service

AI-driven analysis with
rapid reporting time

Giving Patients Access to AI-Driven Decision Support

Growing TAM


Liver

Multiorgan


Chronic liver disease
>20M adults
Liver cancer
>41,000 new cases per year



Obesity
Biggest cause of illness after poverty
Chronic disease of ≥ 2 organs
>100M adults
Solid organ tumors
>1.4M new cases per year




LiverMultiScan



Liver Disease

MRCP+



Biliary and Pancreatic Disease

Hepatica



Liver Cancer

CoverScan



Multi-Organ Disease

FDA Cleared

CPT Codes

Reimbursement

Clinical guidelines

Infrastructure Established for Clinical Success

109M

People covered in the US (1/3 of US population)



47

US States covered

\$950

Medicare

LiverMultiScan reimbursement for hospitals

\$2,100

Commercial

LiverMultiScan reimbursement Technical and professional

2

Distribution Channel partners



+



Calantic™
Digital Solutions

6

applicable CPT codes

Recognized in society guidelines 7



Catalyst for Adoption

Strong Pipeline of MASH Drugs in an increasing MASH market

4

Regulatory Cleared products

Compatibility



750+

Scanners Worldwide



Indiana University Health



Synergy with Pharma Solutions: Big Pharma Commercial Partnerships Through Clinical Trials

FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard

By Angus Liu · Mar 14, 2024 3:56pm

FDA approvals Launches Marketing



Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™




NEWS PROVIDED BY
Eli Lilly and Company →
Jan 04, 2024, 07:30 ET

SHARE THIS ARTICLE
f x in p e t

INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: [LLY](#)) today announced **LillyDirect™**, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.

Madrigal gains as NASH therapy undergoes EU review

Mar. 05, 2024 8:37 AM ET | **Madrigal Pharmaceuticals, Inc. (MDGL) Stock** | ARWR, VKTX, NGM... | By: Dulan Lokuwithana, SA News Editor



Novo Nordisk Boosts Cardiovascular Pipeline With \$1.1 Billion Purchase of Cardior Pharmaceuticals

Cardior focuses on the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart

By [Dominic Chopping](#) [Follow](#)

Updated March 25, 2024 6:59 am ET

6

big pharma contracts

3

in late phase development


Pharma Synergy in Practice: SYNERGY-NASH phase 2 trial study results presented at EASL 2024 ILC

BASELINE NON-INVASIVE TESTS

| Non-invasive test | Total N=190 |
|------------------------|----------------|
| MRI-PDFF (%) | 18.4±7.3 |
| MRI cT1 (msec) | 913.0±97.5 |
| LSM by FibroScan (kPa) | 11.8±5.3 |
| FIB-4 | 1.6±0.8 |
| NIS4 | 0.8±0.2 |
| ELF | 9.8±0.8 |
| Pro-C3 (µg/L) | 128.9±74.6 |

- Baseline non-invasive test results were consistent with the study population of MASH with F2/F3 fibrosis and NAS ≥4

IMAGING



Baseline values are means ±SD. Data are estimates; difference between tirzepatide and placebo are Estimate Difference (95% CI). CIs are not adjusted for multiple comparisons and should not be used to infer definitive treatment effects. The number of participants with test results at baseline varied by test. kPa = kilopascal; LSM = liver stiffness measurement; MRI cT1 = magnetic resonance imaging – iron-corrected T1 mapping; MRI-PDFF = magnetic resonance imaging – proton density fat fraction.

LiverMultiScan cT1 showed dose-dependent and clinically meaningful change across treatment groups.

Providing a Higher Standard of Care Through Integrated Diagnostics

\$10B

NHS investment to build
Community Diagnostics Hubs

40

Centers for the initial phase

800,000

tests capacity to deliver nationally
by March 2022

223

Total NHS Trusts Centers in UK





- ✓ Perspectum is an NHS approved supplier along with GE HealthCare & Philips
- ✓ Located at Perspectum Oxford HQ
- ✓ Diagnostic tests include imaging, physiological measurement, and pathology

Legal Disclaimer

This presentation has been prepared by Perspectum Ltd (“we,” “us,” “our,” “Perspectum” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

In this document, we refer to information regarding potential markets and other industry data. We believe that all such information has been obtained from reliable sources that are customarily relied upon by companies in our industry. However, we have not independently verified any such information.

The trademarks/logos appearing in this presentation belong to their respective owners and do not provide or imply any endorsement, sponsorship or affiliation.

The information contained herein is confidential and may not be reproduced or disclosed in whole or in part.